Eli Lilly — Feb 4, 2026 release

• Pipeline progress included positive Phase 3 results from Taltz and Zepbound used together for adults with active psoriatic arthritis and obesity, orforglipron for people who switched from injectable incretins to oral GLP-1 therapy, and retatrutide for people with obesity and knee osteoarthritis. • Announced an agreement with the U.S. government to expand access to obesity medicines for millions of Americans. • 2026 guidance issued with revenue in the range of $80 billion to $83 billion and non-GAAP EPS in the range of $33.50 to $35.00. INDIANAPOLIS, February 4, 2026 - Eli Lilly and Company (NYSE: LLY) today announced its financial results for the fourth-quarter of 2025 and provided 2026 financial guidance. "2025 was an important year for Lilly," said David A. Ricks, Lilly's chair and CEO. "We reached millions more patients—launching Inluriyo, expanding Mounjaro and Kisunla globally, and submitting orforglipron for approval. We expanded our manufacturing capacity, and through our U.S. government agreement, opened new access to obesity medicines. Entering our 150th year with a deep pipeline and platforms like LillyDirect, we're positioned to reach more patients than ever and expand our global health impact." Eli Lilly and Company | Lilly Corporate Center | Indianapolis, Indiana 46285 | U.S.A. Financial Results $ in millions, except per share data Fourth-Quarter 2025 2024 % Change Revenue $ 19,292  $ 13,533  43% Net income – Reported 6,636  4,410  50% Earnings per share – Reported 7.39  4.88  51% Net income – Non-GAAP 6,771  4,806  41% Earnings per share – Non-GAAP 7.54  5.32  42% A discussion of the non-GAAP financial measures is included below under "Reconciliati